Credit Suisse Ag Crispr Therapeutics Ag Call Options Transaction History

Credit Suisse Ag

5 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q4 2021 Feb 14, 2022	SELL	$70.09 - $111.29 $21,027 - $33,387	-300 Reduced 1.09%	27,100 $2.05 Million
Q3 2021 Nov 12, 2021	SELL	$110.2 - $156.64 $242,440 - $344,607	-2,200 Reduced 7.43%	27,400 $3.07 Million
Q2 2021 Aug 16, 2021	SELL	$100.84 - $161.89 $978,148 - $1.57 Million	-9,700 Reduced 24.68%	29,600 $4.79 Million
Q1 2021 May 14, 2021	BUY	$110.72 - $210.04 $4.01 Million - $7.6 Million	36,200 Added 1167.74%	39,300 $4.79 Million
Q3 2020 Nov 13, 2020	BUY	$78.5 - $100.64 $243,350 - $311,984	3,100 New	3,100 $259,000

490

58M

1.1M

1.9M

Ticker CRSP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 78,009,296
Market Cap $3.02B
Description
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....

Get notified when there are updates to the investment portfolio of Credit Suisse Ag, based on Form 13F filings with the SEC.

Stay updated on Credit Suisse Ag with notifications on news.